Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis

Digestive and Liver Disease

Volumn 49, Issue 4, 2017, Pages 331-337

  Liu, Hai Ning ^a   Wu, Hao ^a   Chen, Yu Zhuo ^a   Chen, Yan Jie ^a   Shen, Xi Zhong ^a   Liu, Tao Tao ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Intestinal microbiota; Irritable bowel syndrome; Meta analysis; Systematic review

Indexed keywords

BACTERIAL COLONIZATION; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; DIARRHEA; DOWN REGULATION; ENTEROCOCCUS; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; PREVOTELLA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; BACTERIUM; CLASSIFICATION; FECES; GENETICS; ISOLATION AND PURIFICATION; META ANALYSIS; MICROBIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

BACTERIAL DNA; PROBIOTIC AGENT;

BACTERIA; DIARRHEA; DNA, BACTERIAL; DOWN-REGULATION; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 85011585838     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2017.01.142     Document Type: Review

References (41)

1. [1] Longstreth, G.F., Thompson, W.G., Chey, W.D., et al. Functional bowel disorders. Gastroenterology 130 (2006), 1480–1491.
2. [2] Kasper, D., Fauci, A., Longo, D., et al. Harrison's principles of internal medicine. 16th ed., 2004, McGraw-Hill, New York.
3. [3] Dupont, H.L., Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Alimentary Pharmacology and Therapeutics 39 (2014), 1033–1042.
4. [4] Ghoshal, U.C., Srivastava, D., Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World Journal of Gastroenterology 20 (2014), 2482–2491.
5. [5] Taverniti, V., Guglielmetti, S., Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World Journal of Gastroenterology 20 (2014), 8821–8836.
6. [6] Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clinical Chemistry 49 (2003), 7–18.
7. [7] Liu, H., Wu, H., Bilegsaikhan, E., et al. Differential expression of intestinal microbiota in colorectal cancer compared with healthy controls: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine 9 (2016), 10923–10930.
8. [8] Hua, C., Cao, H., Changes of intestinal microflora in children with irritable bowel syndrome by SYBR Green I Real Time Fluo-rescent Quantitative PCR Method. Medical and Pharmaceutical Journal of Chinese People's Liberation Army 26 (2014), 93–96.
9. [9] Li, X., Wang, Q., Chu, Y., et al. Analysis of patients with intestinal target bacteria diarrhea type irritable bowel syndrome. Acta Universitatis Medicinalis Anhui 49 (2014), 653–658.
10. [10] Duboc, H., Rainteau, D., Rajca, S., et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterology and Motility 24 (2012), 513–520 e246-7.
11. [11] Tana, C., Umesaki, Y., Imaoka, A., et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterology and Motility 22 (2010), 512–519 e114-5.
12. [12] Zhang, L., Gu, F., Bai, P., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients with 16S rDNA real-time PCR. Shandong Medical Journal 49 (2009), 51–52.
13. [13] Malinen, E., Rinttila, T., Kajander, K., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. The American Journal of Gastroenterology 100 (2005), 373–382.
14. [14] Rinttila, T., Kassinen, A., Malinen, E., et al. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. Journal of Applied Microbiology 97 (2004), 1166–1177.
15. [15] Walter, J., Hertel, C., Tannock, G.W., et al. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Applied and Environmental Microbiology 67 (2001), 2578–2585.
16. [16] Furet, J.P., Firmesse, O., Gourmelon, M., et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiology Ecology 68 (2009), 351–362.
17. [17] Matsuki, T., Watanabe, K., Fujimoto, J., et al. Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Applied and Environmental Microbiology 68 (2002), 5445–5451.
18. [18] Malinen, E., Kassinen, A., Rinttila, T., et al. Comparison of real-time PCR with SYBR Green I or 5′-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. Microbiology 149 (2003), 269–277.
19. [19] Huijsdens, X.W., Linskens, R.K., Mak, M., et al. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. Journal of Clinical Microbiology 40 (2002), 4423–4427.
20. [20] Sokol, H., Pigneur, B., Watterlot, L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 16731–16736.
21. [21] Shukla, R., Ghoshal, U., Dhole, T.N., et al. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Digestive Diseases and Sciences 60 (2015), 2953–2962.
22. [22] Kerckhoffs, A.P., Ben-Amor, K., Samsom, M., et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. Journal of Medical Microbiology 60 (2011), 236–245.
23. [23] Carroll, I.M., Chang, Y.H., Park, J., et al. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathogens, 2, 2010, 19.
24. [24] Krogius-Kurikka, L., Lyra, A., Malinen, E., et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterology, 9, 2009, 95.
25. [25] Lyra, A., Rinttila, T., Nikkila, J., et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World Journal of Gastroenterology 15 (2009), 5936–5945.
26. [26] Kerckhoffs, A.P., Samsom, M., van der Rest, M.E., et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World Journal of Gastroenterology 15 (2009), 2887–2892.
27. [27] Eckburg, P.B., Bik, E.M., Bernstein, C.N., et al. Diversity of the human intestinal microbial flora. Science 308 (2005), 1635–1638.
28. [28] Parkes, G.C., Rayment, N.B., Hudspith, B.N., et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterology and Motility 24 (2012), 31–39.
29. [29] Saulnier, D.M., Riehle, K., Mistretta, T.A., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141 (2011), 1782–1791.
30. [30] Shendure, J., Ji, H., Next-generation DNA sequencing. Nature Biotechnology 26 (2008), 1135–1145.
31. [31] Jeffery, I.B., O'Toole, P.W., Ohman, L., et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61 (2012), 997–1006.
32. [32] Sundin, J., Rangel, I., Fuentes, S., et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Alimentary Pharmacology and Therapeutics 41 (2015), 342–351.
33. [33] Maccaferri, S., Candela, M., Turroni, S., et al. IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation. Gut Microbes 3 (2012), 406–413.
34. [34] Macfarlane, G.T., Allison, C., Gibson, S.A., et al. Contribution of the microflora to proteolysis in the human large intestine. Journal of Applied Bacteriology 64 (1988), 37–46.
35. [35] Buhner, S., Li, Q., Vignali, S., et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 137 (2009), 1425–1434.
36. [36] Ivanov, D., Emonet, C., Foata, F., et al. A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases. The Journal of Biological Chemistry 281 (2006), 17246–17252.
37. [37] Bratten, J.R., Spanier, J., Jones, M.P., Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. The American Journal of Gastroenterology 103 (2008), 958–963.
38. [38] Hwang, L., Low, K., Khoshini, R., et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Digestive Diseases and Sciences 55 (2010), 398–403.
39. [39] Adlard, P.A., Kirov, S.M., Sanderson, K., et al. Pseudomonas aeruginosa as a cause of infectious diarrhoea. Epidemiology and Infection 121 (1998), 237–241.
40. [40] Dulon, S., Leduc, D., Cottrell, G.S., et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. American Journal of Respiratory Cell and Molecular Biology 32 (2005), 411–419.
41. [41] Vergnolle, N., Clinical relevance of proteinase activated receptors (pars) in the gut. Gut 54 (2005), 867–874.